The designation was granted based on positive results from the company's phase 2 study, which evaluated ficlatuzumab as a standalone therapy or in combination with cetuximab. Patients who received the combination therapy showed a superior overall response rate and median progression-free survival.
A fast-track designation is given to speed the review of drugs to treat serious conditions and fulfill an unmet medical need.
Price: 6.81, Change: -0.08, Percent Change:
|Research Alert: CFRA Keeps Buy Opinion On Shares Of ...|
|Technology & Telecommunication Acquisition Prices IPO|
|US Stocks End Week Mixed on Second Weekly Decline Am...|
|Industrial Tech Acquisitions II Closes IPO|
|Churchill Downs Makes Online Gaming President's Job ...|